BIO-TECHNE Corp vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.36B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.45 (market cap $73.20B). The key difference: Vanguard Sht-Term Inflation-Protected Sec Idx ETF is far larger — about 6.4× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Vanguard Sht-Term Inflation-Protected Sec Idx ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Vanguard Sht-Term Inflation-Protected Sec Idx ETF for 91 Days on average.
| TECH | VTIP | |
|---|---|---|
Market Cap | $11.36B | $73.20B |
Volume | 5,390,331 | 2,511,360 |
Sector | Health | — |
52-Week High | $72.61 | $50.46 |
52-Week Low | $43.31 | $48.38 |
Typical Hold Time | 63 Days | 91 Days |
Enterprise Value | $11.39B | — |
Dividend Yield | 0.44% | — |
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
VTIP (Vanguard Short-Term Inflation-Protected Securities ETF) trades at $48.46, showing minimal daily movement with a 0.08% gain. Technical indicators present mixed signals with a bearish overall trend but bullish oscillators. The ETF focuses on short-duration TIPS to hedge inflation while minimizing interest rate sensitivity. Recent institutional buying activity includes NewEdge Advisors increasing their position by 45.5% in Q2 2026.
The ETF offers defensive positioning amid persistent inflation above the Fed's 2% target for 65 consecutive months. While providing inflation protection with reduced duration risk, VTIP faces headwinds from potential Fed policy shifts and competition from other TIPS vehicles. Real yields at multi-decade highs create attractive entry points for inflation-sensitive allocations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →